Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter
Access to hospital-based eye care and reimbursement were policy topics at the…
Phase 2 data for kamuvudine K8, an investigational inflammasome-directed treatment from Inflammasome…
Two transactions announced in September and October 2026 show capital moving through…
GenSight Biologics and the Quinze-Vingts National Ophthalmology Hospital in Paris announced on…
Photo of Stela Vujosevic at the 2025 EURETINA meeting in Paris, France…
Image credit: AdobeStock/jirsak ExSight Ventures invested in RevOpsis Therapeutics, a company developing…
(Image credit: AdobeStock/THANANIT) EYP-1901, known as the vorolanib intravitreal insert, was highlighted…
Photo of Andreas Pollreisz at the 2025 EURETINA meeting in Paris, France…
\n \n CWRU-led research team receives $6.4 million NIH grant \n\n Crain’s…
David Almeida, MD, MBA, PhD, highlights near real surgical systems (NRSS), providing…
(Image credit: ©kwanchaift/AdobeStock) Kalaris Therapeutics announced the company is currently enrolling a…
In celebration of Ophthalmology Times‘ 50th anniversary, we asked leading experts in…
A panelist discusses how a 50-year-old male patient with stabilized keratoconus achieved…
Enter your email address below and subscribe to our newsletter